Efficacy and Safety of Sunitinib Alternate Day Regimen in Patients With Metastatic Renal Cell Carcinoma in Japan: Comparison With Standard 4/2 Schedule

Asia-Pacific Journal of Clinical Oncology - United Kingdom
doi 10.1111/ajco.12849
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Improved Long-Term Clinical Outcomes and Safety Profile of Sunitinib Dosing Schedule With 4/2 Switched to 2/1 in Patients With Metastatic Renal Cell Carcinoma

Journal of Cancer
Oncology
2018English

Sunitinib-Associated Hypertension and Neutropenia as Efficacy Biomarkers in Metastatic Renal Cell Carcinoma Patients

British Journal of Cancer
Cancer ResearchOncology
2015English

Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

Therapeutic Advances in Urology
Urology
2016English

Safety and Efficacy of Sunitinib for Advanced Non-Clear Cell Renal Cell Carcinoma

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2015English

Sunitinib Causes Macrocytosis in Patients With Advanced Renal Cell Carcinoma

Current Oncology
Oncology
2010English

A Phase 2 Trial of Sunitinib in Patients With Advanced Non–clear Cell Renal Cell Carcinoma

European Urology
Urology
2012English

Association of Angiopoietin-2 and Ki-67 Expression With Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma

PLoS ONE
Multidisciplinary
2016English

Reversible Myocardial Dysfunction in a Young Woman With Metastatic Renal Cell Carcinoma Treated With Sunitinib

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2009English

High-Dose Interleukin 2 in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Features

PLoS ONE
Multidisciplinary
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy